Catherine Zhu, Elvis Martinez-Jaramillo, Moshe Ben Shoshan, Elena Netchiporouk, May Chergui, Michael Fein
{"title":"Schnitzler Syndrome without Monoclonal Gammopathy: A systematic review and case presentation.","authors":"Catherine Zhu, Elvis Martinez-Jaramillo, Moshe Ben Shoshan, Elena Netchiporouk, May Chergui, Michael Fein","doi":"10.1093/ced/llaf403","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Schnitzler syndrome (SS) is a rare autoinflammatory disorder that presents with chronic urticarial rash, neutrophilic urticarial dermatosis, monoclonal IgG or IgM gammopathy, recurrent fever, joint and/or bone pain and enlarged lymph nodes, spleen, and/or liver. Several cases in the literature have described incomplete variants of SS that lack monoclonal gammopathy. This systematic review aims to analyze the current literature regarding the features of Schnitzler-like Syndrome (SLS) and their treatment outcomes; we also report our own case of SLS.</p><p><strong>Methods: </strong>A systematic search of MEDLINE, Embase, Scopus and PubMed was performed (PROSPERO: CRD42024548245). All articles in English or French were included, and no publication date restrictions were applied. All articles with original data, clinical features and treatment outcomes were included. Two reviewers independently conducted screenings and conflicts were resolved by a third reviewer if necessary.</p><p><strong>Results: </strong>15 studies (13 case reports and 2 case series) met inclusion criteria, in addition to one case from our own experience, yielding a total of 18 patients. The majority of our population was male (55.6%) with a median age at diagnosis of 57.5 (IQR=44.8, 62.8). The majority of our patients had absent monoclonal gammopathy (n = 14; 77.8%), and four (22.2%) had delayed-onset monoclonal gammopathy. Antihistamines were the most common treatment (n=17; 94.4%), followed by anakinra (n=14; 77.8%), prednisone (n = 9; 50.0%), unspecified systemic corticosteroids (n=8; 44.4%), omalizumab (n=8; 44.4%), colchicine (n = 5; 27.8%), dapsone (n = 6; 33.3%), cyclosporine (n = 4; 22.2%), canakinumab (n=4; 22.2%), hydroxychloroquine (n=2; 11.1%) and thalidomide (n=1; 5.6%). Of the 14 patients treated with anakinra, 92.9% (n = 13/14) achieved a complete response (CR).</p><p><strong>Conclusions: </strong>Our findings raise the hypothesis that monoclonal gammopathy may not be an obligate criterion for Schnitzler syndrome. We propose this as a consideration for future consensus discussions, emphasizing the potential benefits of early recognition and timely IL-1 inhibitor therapy to improve patient outcomes.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ced/llaf403","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Schnitzler syndrome (SS) is a rare autoinflammatory disorder that presents with chronic urticarial rash, neutrophilic urticarial dermatosis, monoclonal IgG or IgM gammopathy, recurrent fever, joint and/or bone pain and enlarged lymph nodes, spleen, and/or liver. Several cases in the literature have described incomplete variants of SS that lack monoclonal gammopathy. This systematic review aims to analyze the current literature regarding the features of Schnitzler-like Syndrome (SLS) and their treatment outcomes; we also report our own case of SLS.
Methods: A systematic search of MEDLINE, Embase, Scopus and PubMed was performed (PROSPERO: CRD42024548245). All articles in English or French were included, and no publication date restrictions were applied. All articles with original data, clinical features and treatment outcomes were included. Two reviewers independently conducted screenings and conflicts were resolved by a third reviewer if necessary.
Results: 15 studies (13 case reports and 2 case series) met inclusion criteria, in addition to one case from our own experience, yielding a total of 18 patients. The majority of our population was male (55.6%) with a median age at diagnosis of 57.5 (IQR=44.8, 62.8). The majority of our patients had absent monoclonal gammopathy (n = 14; 77.8%), and four (22.2%) had delayed-onset monoclonal gammopathy. Antihistamines were the most common treatment (n=17; 94.4%), followed by anakinra (n=14; 77.8%), prednisone (n = 9; 50.0%), unspecified systemic corticosteroids (n=8; 44.4%), omalizumab (n=8; 44.4%), colchicine (n = 5; 27.8%), dapsone (n = 6; 33.3%), cyclosporine (n = 4; 22.2%), canakinumab (n=4; 22.2%), hydroxychloroquine (n=2; 11.1%) and thalidomide (n=1; 5.6%). Of the 14 patients treated with anakinra, 92.9% (n = 13/14) achieved a complete response (CR).
Conclusions: Our findings raise the hypothesis that monoclonal gammopathy may not be an obligate criterion for Schnitzler syndrome. We propose this as a consideration for future consensus discussions, emphasizing the potential benefits of early recognition and timely IL-1 inhibitor therapy to improve patient outcomes.
期刊介绍:
Clinical and Experimental Dermatology (CED) is a unique provider of relevant and educational material for practising clinicians and dermatological researchers. We support continuing professional development (CPD) of dermatology specialists to advance the understanding, management and treatment of skin disease in order to improve patient outcomes.